Identification of tumor antigens and immunogenic cell death-related subtypes for the improvement of immunotherapy of breast cancer

ABSTRACT: The current immunotherapy strategy for breast cancer is limited. Tumor neoantigens have been proven to be a promising biomarker and potential target of immunotherapy in a variety of tumors. However, their effectiveness for breast cancer remains unclear. Immunogenic cell death (ICD) is a regulated form of cell death that can reshape the tumor immune microenvironment and activate adaptive immune responses. To this end, we screened potential antigens that could be used both for the development of immunotherapy and differentiating the patient-specific immune responses based on ICD-related risk signatures, in order to formulate an accurate scheme for breast cancer immunotherapy. We retrieved the gene expression profiles of the breast invasive cancer cohort and their corresponding clinical contr

SUBMITTER:  

PROVIDER: S-EPMC9641162 | biostudies-literature | 2022 Jan

REPOSITORIES: biostudies-literature